EUROSETS
17.7.2024 11:13:26 CEST | Business Wire | Press release
The baby was affected by a viral infection, leaving him unable to breathe. Thanks to a state-of-the-art device, used for the first time in the world in the Caribbean, the medical-surgical team was able to save the infant.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716825866/en/
Colibrì, the lightest life-saving device that replaces the function of the heart and lungs (Photo: Eurosets)
The Colibri (hummingbird), one of the national symbols of Martinique, is also the name of an innovative, next-generation ECMO system, designed and manufactured by Eurosets, an Italian company based in the biomedical district of Medolla (MO), which enabled the medical-surgical team at Martinique University Hospital to save the life of a one-and-a-half-month-old child suffering from acute bronchiolitis.
The baby was born in Guadeloupe and weighed just 5kg. He was unable to breathe independently due to the viral infection, which subsequently led to heart failure. The infant was immediately transferred to the CHU de Martinique (CHUM), the only French hospital in the Caribbean with a third-level pediatric intensive care unit but, due the child's unstable condition, it was impossible to move him.
Following first-rate coordination with the neonatal intensive care unit at Guadeloupe University Hospital, the Martinique team from the UMAC (Unité Mobile d'Assistance Circulatoire) was able to travel to the neighboring island and connect the new ECMO system in the jugulo-carotid position to the newborn, allowing the infant to be transferred safely by helicopter.
The procedure was a success thanks to the seamless cooperation between Dr Xavier Beretta-Piccoli, pediatric intensive care specialist, and Dr Fabio Cuttone, head of pediatric cardiac surgery at the CHUM.
This intervention marked the world's first installation of a third-generation transportable device entirely designed and adapted for infants and children. The UMAC 972, consisting of a medical (intensive care specialist, cardiac surgeon) and paramedical (perfusionist) team, a pioneer in mobile circulatory assistance in the Caribbean archipelago and unique in terms of know-how and experience, played a vital role in the success of this medical treatment.
The infant was admitted to the CHUM pediatric intensive care unit. He received care and was attached to Colibri for five days until his lungs and heart functioned normally. Subsequently, having fully recovered from his bronchiolitis, the child was discharged from hospital and returned to Guadeloupe after 15 days in hospital. He will have to be monitored periodically, like all babies who have been in intensive care. He is now out of danger.
This ground-breaking treatment, the result of cooperation between the Martinique University Hospital, Eurosets, the CTM (Collectivité Territoriale de la Martinique) and European funding from React-UE (Recovery assistance for cohesion and the territories of Europe), finally provides the children of the Caribbean archipelago with a life-saving strategy at the forefront of technology.
Colibri is the world's lightest life-saving device capable of temporarily replacing cardiac and pulmonary functions. It is the only third-generation transportable system entirely designed and adapted to newborns and children.
In addition to adult patients, the device can be used on pediatric or even neonatal patients thanks to a dedicated centrifugal pump. The technology is suitable for use in a variety of therapeutic applications, including extracorporeal cardiopulmonary resuscitation (E-CPR) in cardiac arrest, extracorporeal membrane oxygenation (ECMO) and mechanical circulatory support (MCS).
Equipped with a centrifugal pump with magnetic levitation and a device capable of artificially oxygenating the blood, as well as offering excellent ergonomics, the Colibri is a high-performance circulatory assistance system, ideal in all situations in which intra- and extra-hospital transportability are crucial, including the most extreme rescue operations, such as airborne medical evacuations (by helicopter, passenger airline or military aircraft), scenarios that are common in the Caribbean region.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be crossreferenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716825866/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
